Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher DeRenzo

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Journal of Clinical & Cellular Immunology|June 18, 2016
Genetically Modified T-cell Therapy for the Treatment of Osteosarcoma: An UpdateChristopher DeRenzo, Stephen Gottschalk
Frontiers in Immunology|March 5, 2019
Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid TumorsChristopher DeRenzo, Stephen Gottschalk
Advances in Experimental Medicine and Biology|June 14, 2014
Genetically modified T-cell therapy for osteosarcomaChristopher DeRenzo, Stephen Gottschalk
Advances in Experimental Medicine and Biology|June 3, 2020
Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020sChristopher DeRenzo, Stephen Gottschalk
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
The Landscape of CAR T Cells Beyond Acute Lymphoblastic Leukemia for Pediatric Solid TumorsChristopher DeRenzo, Giedre Krenciute, Stephen Gottschalk
EJC Paediatric Oncology|July 3, 2024
CAR T cells redirected to B7-H3 for pediatric solid tumors: Current status and future perspectivesRebecca Epperly, Stephen Gottschalk, Christopher DeRenzo
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 26, 2020
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?Jessica Wagner, Elizabeth Wickman, Christopher DeRenzo, et al.
Frontiers in Oncology|January 16, 2014
Genetically modified T cells to target glioblastomaSimone Krebs, Tania G Rodríguez-Cruz, Christopher Derenzo, et al.
Pediatric Blood & Cancer|October 16, 2018
Salvage regimens for pediatric patients with relapsed nasopharyngeal carcinomaChristopher DeRenzo, Catherine Lam, Carlos Rodriguez-Galindo, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 2, 2024
A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKCα activationHa Won Lee, Carla O'Reilly, Alex N Beckett, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Journal of Clinical & Cellular Immunology|June 18, 2016
Genetically Modified T-cell Therapy for the Treatment of Osteosarcoma: An UpdateChristopher DeRenzo, Stephen Gottschalk
Frontiers in Immunology|March 5, 2019
Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid TumorsChristopher DeRenzo, Stephen Gottschalk
Advances in Experimental Medicine and Biology|June 14, 2014
Genetically modified T-cell therapy for osteosarcomaChristopher DeRenzo, Stephen Gottschalk
Advances in Experimental Medicine and Biology|June 3, 2020
Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020sChristopher DeRenzo, Stephen Gottschalk
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
The Landscape of CAR T Cells Beyond Acute Lymphoblastic Leukemia for Pediatric Solid TumorsChristopher DeRenzo, Giedre Krenciute, Stephen Gottschalk
EJC Paediatric Oncology|July 3, 2024
CAR T cells redirected to B7-H3 for pediatric solid tumors: Current status and future perspectivesRebecca Epperly, Stephen Gottschalk, Christopher DeRenzo
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 26, 2020
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?Jessica Wagner, Elizabeth Wickman, Christopher DeRenzo, et al.
Frontiers in Oncology|January 16, 2014
Genetically modified T cells to target glioblastomaSimone Krebs, Tania G Rodríguez-Cruz, Christopher Derenzo, et al.
Pediatric Blood & Cancer|October 16, 2018
Salvage regimens for pediatric patients with relapsed nasopharyngeal carcinomaChristopher DeRenzo, Catherine Lam, Carlos Rodriguez-Galindo, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 2, 2024
A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKCα activationHa Won Lee, Carla O'Reilly, Alex N Beckett, et al.
Pageof 3